to evaluate the APPs in conjunction with traditional demographic, clinical, blood (hematocrit, total plasma protein, WBC, lactate, glucose) and PF (total protein, hemolysis) variables. Robustness of the models was evaluated by multiple splitting's of the data into training and test-sets.
Results: Twenty-three cases of LCV ≥360 o were included in this study. Thirteen of 23 (57%) horses survived to discharge. A cutoff value of <2.1 PHH3 + cells per crypt correctly predicted death with 100% sensitivity (95% CI; 69.15-100%) and 84.62% specificity (95% CI; 54.55%-99.08%). LCV cases with <2.1 PHH3 + cells per crypt were 96.6 times more likely to die (95% CI; 4.142-2253 and P < 0.0001). Other biomarkers did not predict case outcome.
Conclusions: PHH3 immunohistochemical analysis provides accurate prognosis in cases of LCV in the post-operative period. Additional cases will improve the utility of this model for decisions regarding surgery and recovery.
